Blandt HBeAg- negative patienter var telbivudin ikke dårligere end lamivudin (75, 2% og 77, 2% respondenter; p = 0, 6187).
In HBeAg-negative patients, telbivudine was non-inferior to lamivudine (75.2% and 77.2% responders; p = 0.6187).